Thousand Oaks pharma giant Amgen Inc. is making a series of C-suite changes, triggered by the retirement announcement of Chief Technology Officer David Reese.

Reese, 63, is retiring effective June 1. He has served as the company’s first chief technology officer since 2023.

Sean Bruich, the current senior vice president of artificial intelligence and data, will be taking over the chief technology officer post on June 1. These changes are in turn resulting into others:

James Bradner, the current executive vice president of research and development, will add artificial intelligence and data to his portfolio; and Murdo Gordon, the current executive commercial operations, will add global markets and policy as well as government affairs and policy, to his responsibilities.Another C-suite executive, Paul Burton, will retain his chief medical officer title; his duties appear unchanged.

Robert Bradway will remain as chief executive and chairman. Although he is roughly the same age as the retiring Reese, there has been no indication of a forthcoming chief executive transition.

Retiring after 21 years

Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of research and development from 2018 to 2023.

According to the announcement, Reese led approvals of numerous innovative medicines and biosimilars, advanced a pipeline of potential new therapies and strengthened discovery research capabilities. As chief technology officer, he encouraged the early adoption of technology and artificial intelligence across all facets of the business.

“Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift,” chief executive Bradway said in the announcement. “The capabilities he built position us to advance what we call convergent innovation and strengthen our ability to serve patients in the years ahead.”